GovChime
Notice ID: f5f4a62498e140b79a82211833c25330Award NoticeAwarded

INNOVATIONS IN FUNCTIONAL B CELL EPITOPE DISCOVERY

Awarded on September 25, 2024. Full description on SAM.gov.

Awarded tounder 75N93024C00055 (source: SAM.gov award notice)• $2.1M

Overview

Posted
September 26, 2024
Notice type
Award Notice
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of Health and Human Services

Notice details

Place of performance
Redwood City, CA, 94063
Last updated
Dec 4, 2025
Award date
Sep 25, 2024
Award amount (SAM.gov award notice)
$2.1M

Identifiers

Solicitation number
BAA-NIAID-75N93023R00002
Notice ID
f5f4a62498e140b79a82211833c25330
Award number (PIID)
75N93024C00055

Description

Attached is Amendment 1 which answers questions and updates some of the links in Section J. This program supports innovative research for high throughput discovery and validation of novel B cell epitopes associated with infectious pathogens or vaccines against them, autoimmune diseases, allergens, or HLA epitopes associated with cell/organ/tissue transplant rejection or tolerance. The focus of each proposal must be on one of the four topics listed below. 1. Infectious disease and/or vaccine responses, including pathogens with pandemic potential. 2. Autoimmune disease. This research area also could include the identification of pathogen-specific epitopes that are implicated in induction of autoimmune disease. 3. Allergy to aeroallergens, food allergens or drugs. 4. Transplantation of cells, tissues or organs. Studies related to HIV will not be supported under this program.

Full description on SAM.gov

Award Overview

Award Number

75N93024C00055

Award Amount (SAM.gov award notice)

$2.1M

Award Date

Sep 25, 2024

Awardee

Awardee UEI

HD1WMN6945W6

Awardee CAGE Code

1HEX5

Original Solicitation

Notice ID: f5f4a62498e140b79a82211833c25330

Posted Date: Sep 26, 2024

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

5
  • 75N94020F00001
    UNIVERSITY OF WASHINGTON
    Department of Health and Human ServicesNAICS 541714
    $250.4KSigned Sep 3, 2026
  • 75N94020F00001
    UNIVERSITY OF WASHINGTON
    Department of Health and Human ServicesNAICS 541714
    $220.0KSigned Sep 22, 2025
  • 75N92018F00001
    UNIVERSITY OF WASHINGTON
    Department of Health and Human ServicesNAICS 541714
    $11.2MSigned Sep 10, 2025
  • 75N94020F00001
    UNIVERSITY OF WASHINGTON
    Department of Health and Human ServicesNAICS 541714
    $184.4KSigned May 28, 2025
  • 75N95023F00001
    UNIVERSITY OF WASHINGTON
    Department of Health and Human ServicesNAICS 541714
    $7.1KSigned May 9, 2025

Contacts

Documents

No documents available.

Lifecycle

Solicitation:BAA-NIAID-75N93023R00002
  1. Pre-Solicitation
  2. Solicitation
  3. Awarded

This opportunity has been awarded.

  1. Pre-SolicitationMay 5, 2023

    INNOVATIONS IN FUNCTIONAL B CELL EPITOPE DISCOVERY

    Notice ad02768b576346718f8bacd63d2cb5ea on SAM.gov

  2. 3×
    SolicitationMay 23, 2023

    INNOVATIONS IN FUNCTIONAL B CELL EPITOPE DISCOVERY

    Notice c19a952370bb4bca8f381c57f46e7152 on SAM.gov

  3. 6×
    AwardedCurrentSep 26, 2024

    INNOVATIONS IN FUNCTIONAL B CELL EPITOPE DISCOVERY

    Notice f5f4a62498e140b79a82211833c25330 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
NOTICE OF A PROPOSED CONTRACT ACTION NON-COMPETITIVE Notice ID: 75N95022C00004 Contract Opportunity Type: Presolicitation Response Date: November 27, 2026, at 1:00 PM Eastern Time (15 days) Classification: No Small Business Set Aside Used Product Service Code: AN11 NAICS Code: 541715 Place of Performance: Blank Description PURSUANT TO RFO 5.101 — PRESOLICITATION NOTICE, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION. THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022C00004 WITH VIRGINIA COMMONWEALTH UNIVERSITY. THIS IS NOT A SOLICITATION OR A REQUEST FOR COMPETITIVE PROPOSALS. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), through the Addiction Treatment Discovery Program (ATDP) within NIDA’s Division of Therapeutics and Medical Consequences (DTMC), intends to modify Single Award Contract No. 75N95022C00004, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA,” to extend the period of performance by 12-months through February 21, 2027. All other terms and conditions remain unchanged. This modification will allow for the continuation of ongoing research conducted under the Preclinical Medications Discovery and Abuse Liability Testing program for NIDA and prevent any delays or disruption to the development of therapeutics essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed. REGULATORY AUTHORITY The resultant modification will include all applicable provisions and clauses of the Revolutionary FAR Overhaul (RFO) Initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26. STATUTORY AUTHORITY This modification is conducted under the authority of 41 U.S.C. 3304(a)(1) and in accordance with RFO 6.103-1 Only one responsible source and no other supplies or services will satisfy agency requirements. CLOSING STATEMENT THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by the closing date and time of this announcement and must reference the Project Title, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA.” Responses must be submitted electronically to Shayna Simpson, Contracting Officer, at shayna.simpson@nih.gov. Mailed and faxed responses will not be accepted. PRIMARY POINT OF CONTACT: Shayna Simpson Email: shayna.simpson@nih.gov Phone: 301-402-9712
68%
Pre-Solicitation11/27/2026
Anticipated Period of Performance The anticipated period of performance is February 1, 2027 through January 31, 2028, with an option to extend services for an additional 6 month period, through July 31, 2028. Anticipated award date: February 1, 2027 The NAICS Code is 541715. Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology, and Transplantation (DAIT) has a requirement to support a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. The major clinical research programs to be supported by this solicitation include, Autoimmunity Centers of Excellence and Immune Tolerance Network (ACE), as well as investigator initiated clinical trials (IICT), and other clinical trials or study activities supported by NIAID herein collectively referred to as NIAID supported research. Description Topic Title: Autoimmune Diseases Statistical & Clinical Coordinating Center (ADSCCC) The Division of Allergy, Immunology, and Transplantation (DAIT), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), project is for work related to the contract below: “Autoimmune Diseases Statistical & Clinical Coordinating Center (AD-SCCC)”, RHO Federal Systems Division, Inc. (Contract 75N93022C00003) This contract was awarded on a competitive basis for a five-year period from February 1, 2022 through January 31, 2027. A term type/level of effort contract was awarded for the delivery of 56,170 direct labor hours per year for Years 1-5. The total value of the contract is $49,268,667 and includes options for extension of the term for a total performance period of 5 years and options for increases in the level of effort, with the purpose of establishing an Autoimmune Diseases Statistical & Clinical Coordinating Center (AD- SCCC) that will provide a broad range of support critical for the design, development, execution, and analysis of clinical research sponsored by NIAID in autoimmune diseases and diseases related to mucosal immunology and primary immune deficiencies. The scope of clinical research to be supported by the AD- SCCC includes: (i) clinical trials at all phases to evaluate the safety and efficacy of investigational products and innovative approaches for disease treatment and prevention; (ii) studies of underlying mechanisms as integral components of clinical trials; (iii) clinical studies (e.g., genetic studies, microbiome studies, surveys of current therapies, etc.); and (iv) surrogate/biomarker studies. The scope of statistical and clinical support functions to be performed by the AD-SCCC includes statistical design and analysis; protocol development; study initiation and management; clinical safety and pharmacovigilance support; safety oversight; management of clinical study collaboration portals; manuscript preparation and management of sample repositories. The NIAID, NIH, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. The causes, pathogenesis, diagnosis, treatment, and prevention of autoimmune diseases are major areas of emphasis for NIAID’s Division of Allergy, Immunology, and Transplantation (DAIT). DAIT pursues research on autoimmune diseases by supporting investigator-initiated research projects, cooperative clinical studies, national networks of research centers, and demonstration and education research projects. A critical component of the Division’s mission focuses on clinical research to develop new and/or improved strategies to treat or prevent autoimmune diseases through rigorous evaluations of the safety and efficacy of investigational products and therapeutic interventions, studies to elucidate underlying mechanisms of disease, studies to develop and evaluate surrogate/biomarkers of disease stage, severity and progression, and clinical studies of disease natural history. The purpose of this acquisition is to extend the period of performance of the current contract (through July 31, 2028), beginning February 1, 2027, thereby maintaining the same direct labor hours to maintain ongoing clinical trial operations while DAIT completes the competition under the Clinical Data, Safety, and Coordinating Centers (CDSCC) NOFO. The extension retains the existing scope and contract type. The required research and development clinical trial activities are severable in nature, the 18-month extension will be structured as two discrete option periods. Specifically, the Contractor will be responsible for the following: A. Statistical Design Provide expertise, advice and assistance pin the development of statistical design plans for the development of concept and full study proposals for NIAID supported clinical research; Provide assistance in the preparation of concept and full proposals and study-specific protocols; Provide assistance in the preparation of concept and full proposals and protocols for mechanistic studies; Provide support for preclinical safety study evaluation by providing statistical expertise for, and participate in, evaluating the accuracy and validity of data from preclinical safety studies in support of clinical trials if applicable; Provide assistance for clinical trials and mechanistic studies post-study initiation. B. Statistical Analysis Development and preparation of the Statistical Analysis Plan (SAP) for each clinical trial in conjunction with the Study Management Teams (SMTs); Preparation of interim and final analyses; Preparation of summary data reports; Development and preparation of results for posting as required by ClinicalTrials.gov; Review of the accuracy and completeness of statistical data and data analyses for all abstracts, manuscripts, and presentations reporting on the clinical studies conducted by the relevant NIAID-sponsored networks and investigators prior to presentation or submission for publication. Collaboration with NIAID-supported research, including the NIAID Clinical Data and Safety Management Center (CDSMC); C. Protocol Development and Study Initiation Provide expert advice and assistance to SMTs in the development of protocols for clinical trials and mechanistic studies; Provide expert advice, assistance and coordination in the preparation, writing, review and approval of protocol-related documents and materials in collaboration with NIAID, SMTs, and the CDSMC and other NIAID supported research. D. Data Management and Reporting E. Clinical Safety and Pharmacovigilance Center Support F. Safety Oversight Structure Support G. Clinical Study Internet-Based Collaboration Portals H. Training I. Repository of Biological Specimens J. Other Technical and Administrative Support K. Scientific and Technical Personnel L. Facilities, Equipment and Other Resources M. Quality Assurance/Quality Control N. Overall Project Management O. Initial and Final Transitions The NIAID intends to negotiate, under the authority of RFO - FAR Part 6.302-1 and HHSAR Part 306.302-1, on a sole source basis with Rho, to modify the existing contract to extend the current contract by a total of 18-months [Term Option 5 (12-months, February 1, 2027 through January 31, 2028), and Term Option 6 (6-months, February 1, 2028 through July 31, 2028)]. Due to the complex nature of DAIT clinical trial operations and the need for a contractor to perform the required AD-SCCC services during the interim period, the requirement is to maintain support for the existing portfolio without an interruption in protocol operations, statistical support, data coordination, or safety oversight beginning February 1, 2027. Rho’s demonstrated personnel qualifications, staffing, relevant experience, and current protocol-specific knowledge support its ability to meet that requirement. Attempting to bring in a new contractor would result in a significant disruption to critical services and could jeopardize participant safety and data integrity. Using the current contractor for the extension of services allows for continuity of operations in this highly regulated environment and helps to ensure we are able to maintain during this interim period the services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. This notice of intent is not a request for competitive proposals. However, responsible sources may express their interest by submitting a capability statement. All capability statements received within fifteen days from the date of the publication of this notice will be considered by the Government. A determination by the Government not to compete this proposed contract action based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. This proposed acquisition was previously published under a Research and Development Sources Sought Notice that was posted on the System for Award Management (SAM.gov) website on February 20, 2026 as notice number HHS–NIH–NIAID–RDSS–26–75N93026R00009.
68%
Pre-Solicitation12/01/2026
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation. An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process. Please note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach. Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses. The scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial. The scope of work must include a clinical trial. Offerors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses. A strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery. Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted: Viral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html Encephalitic paramyxoviruses (e.g. hendra virus, nipah virus) Picornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus) At least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales Adjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered. Important notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome. Preventative treatments are not included in the scope of this Research Area. A therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of </= 40 amino acids, monoclonal antibodies, nanobodies, nanobody conjugate/fusion products, microbiome-based therapeutics or bacteriophages. Research Area 002 will support lead optimization, pre-clinical Investigational New Drug (IND) enabling studies, and Phase 1 clinical trials (or proof of concept Phase 2 clinical trials) of lead candidates with demonstrated therapeutic activities. This includes support for traditional, novel (e.g., small molecules) and non-traditional (e.g., including but not limited to phage, and host-directed) therapeutics for infectious diseases where patients lack effective interventions, as well as therapeutics that promote host-mediated resolution of disease. The scope of support differs depending on the developmental stage of the project being proposed, which is further discussed in the BAA Solicitation. Research Area 003 - In Vitro Diagnostics The objective of Research Area 003 is to develop innovative, technology platforms that will speed detection and identification of infectious viruses covering a broad panel of virus families, including viruses causing acute infections as well as those causing chronic infections. Technology platform innovation to achieve faster actionable sequencing results (approaching 2 hr) direct from primary clinical specimens, as well as more accessible workflow and configuration (i.e., point-of-care) are preferred. Furthermore, full sample-to-answer platform solutions are preferred. The system should accept specimen volumes from 0.5 to 5 milliliters (mL). The system should include nearly full automation (little or no hands-on activity after specimen has been loaded into system). Sample preparation components of the system should yield sufficient analyte recovery from a starting titer of 10-100 genomic copies per mL of biofluid for downstream analysis, including detection, identification, and characterization of the nucleic acid material. Innovations during platform development might include, for example: Automated sample prep for high recovery from low pathogen load. Faster specimen-to-answer for total test time <2 hours. Broad viral pathogen detection capability, covering one or more members of the priority pathogen families (see below). Targeted, or even untargeted pathogen detection and identification via long-read sequencing or other detection methods. Multiple specimen throughput per run for reduced cost. Analytical sensitivity approaching 5-50 genome copies per mL of starting biofluid. Assay reconfigurability to respond rapidly to a novel pathogen in days or weeks rather than months (i.e., agnostic diagnostic solution). Priority Pathogens The diagnostic test system must detect analytes from at least one, and preferably several, of the following agents and markers: Arenaviridae (e.g., Lassa virus) Phenuviridae (e.g., Rift Valley fever virus) Peribunyayviridae (e.g., Oropouche virus) Hantaviridae (e.g., Hantavirus) Nairoviridae (e.g., Crimean Congo Hemorrhagic fever virus) Filoviridae (e.g., Sudan virus, Ebola virus, Marburg virus) Flaviviridae (e.g., Hepatitis C virus, West Nile Virus) Paramyxoviridae (e.g., Nipah virus) Togaviridae (e.g., Chikungunya virus) Picornaviridae (e.g., Enterovirus) PROPOSAL SUBMISSION: Proposals Due Date and Time – December 8, 2026, 3:00 PM Eastern Time For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by any other method is not permitted. For directions on using eCPS, go to the website: https://ecps.nih.gov and thenclick on "How to Submit."
68%
Solicitation12/08/2026
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award.
68%
AwardedOpen
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award.
68%
AwardedOpen

Additional Details

Solicitation Number

BAA-NIAID-75N93023R00002

Archive Date

Oct 10, 2024

Office Address

BETHESDA, MD, 20892